
Glen Philip Westall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4172520/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Revision of the 1996 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Lung Rejection. Journal of Heart and Lung Transplantation, 2007, 26, 1229-1242.	0.3	1,309
2	Antibody-mediated rejection of the lung: A consensus report of the International Society for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation, 2016, 35, 397-406.	0.3	316
3	Circulating T _{FH} cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity. Science Translational Medicine, 2018, 10, .	5.8	196
4	Human CD8+ T cell cross-reactivity across influenza A, B and C viruses. Nature Immunology, 2019, 20, 613-625.	7.0	180
5	MAIT cells protect against pulmonary Legionella longbeachae infection. Nature Communications, 2018, 9, 3350.	5.8	177
6	Influenza-specific lung-resident memory T cells are proliferative and polyfunctional and maintain diverse TCR profiles. Journal of Clinical Investigation, 2018, 128, 721-733.	3.9	147
7	Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology, 2014, 19, 1215-1221.	1.3	124
8	A Feasibility and Safety Study of Bronchoscopic Thermal Vapor Ablation: A Novel Emphysema Therapy. Annals of Thoracic Surgery, 2009, 88, 1993-1998.	0.7	116
9	Oxygen therapy for interstitial lung disease: a systematic review. European Respiratory Review, 2017, 26, 160080.	3.0	114
10	CD8+ TÂcells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity. Immunity, 2021, 54, 1066-1082.e5.	6.6	106
11	Human Cytomegalovirus Load in Plasma and Bronchoalveolar Lavage Fluid: A Longitudinal Study of Lung Transplant Recipients. Journal of Infectious Diseases, 2004, 190, 1076-1083.	1.9	102
12	A class of γδT cell receptors recognize the underside of the antigen-presenting molecule MR1. Science, 2019, 366, 1522-1527.	6.0	98
13	Clinical outcomes of lung transplant recipients with telomerase mutations. Journal of Heart and Lung Transplantation, 2015, 34, 1318-1324.	0.3	82
14	C3d and C4d Deposition Early After Lung Transplantation. Journal of Heart and Lung Transplantation, 2008, 27, 722-728.	0.3	80
15	Acute Fibrinoid Organizing Pneumonia after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1360-1368.	2.5	78
16	Be honest and help me prepare for the future. Chronic Respiratory Disease, 2015, 12, 93-101.	1.0	71
17	Cyclophosphamide for connective tissue disease-associated interstitial lung disease. The Cochrane Library, 2018, 2018, CD010908.	1.5	70
18	Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation, 2003, 75, 2064-2068.	0.5	67

#	Article	IF	CITATIONS
19	Mitochondrial dysfunction contributes to the senescent phenotype of <scp>IPF</scp> lung fibroblasts. Journal of Cellular and Molecular Medicine, 2018, 22, 5847-5861.	1.6	65
20	Single-Cell Approach to Influenza-Specific CD8+ T Cell Receptor Repertoires Across Different Age Groups, Tissues, and Following Influenza Virus Infection. Frontiers in Immunology, 2018, 9, 1453.	2.2	63
21	A Randomized Study of Quantiferon CMV-directed Versus Fixed-duration Valganciclovir Prophylaxis to Reduce Late CMV After Lung Transplantation. Transplantation, 2019, 103, 1005-1013.	0.5	55
22	Continued Successful Evolution of Extended Criteria Donor Lungs for Transplantation. Annals of Thoracic Surgery, 2017, 104, 1702-1709.	0.7	54
23	STAT3 Regulates the Onset of Oxidant-induced Senescence in Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 2019, 61, 61-73.	1.4	52
24	Evolving experience of treating antibody-mediated rejection following lung transplantation. Transplant Immunology, 2014, 31, 75-80.	0.6	50
25	Cadaveric Lobar Lung Transplantation: Technical Aspects. Annals of Thoracic Surgery, 2012, 93, 1836-1842.	0.7	49
26	The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis. International Journal of Biochemistry and Cell Biology, 2018, 97, 108-117.	1.2	49
27	Immunosuppression for Lung Transplantation. Drugs, 2007, 67, 1531-1539.	4.9	46
28	Definitions of Warm Ischemic Time When Using Controlled Donation After Cardiac Death Lung Donors. Transplantation, 2008, 86, 1702-1706.	0.5	46
29	Molecular assessment of rejection and injury in lung transplant biopsies. Journal of Heart and Lung Transplantation, 2019, 38, 504-513.	0.3	46
30	Evaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres. BMC Pulmonary Medicine, 2016, 16, 22.	0.8	45
31	Bystander Activation of Pulmonary Trm Cells Attenuates the Severity of Bacterial Pneumonia by Enhancing Neutrophil Recruitment. Cell Reports, 2019, 29, 4236-4244.e3.	2.9	44
32	Selection and Management of the Lung Donor. Clinics in Chest Medicine, 2011, 32, 223-232.	0.8	42
33	The plasminogen activation system: new targets in lung inflammation and remodeling. Current Opinion in Pharmacology, 2013, 13, 386-393.	1.7	41
34	Impact of Commonly Used Transplant Immunosuppressive Drugs on Human NK Cell Function Is Dependent upon Stimulation Condition. PLoS ONE, 2013, 8, e60144.	1.1	41
35	Human γδTâ€eell receptor repertoire is shaped by influenza viruses, age and tissue compartmentalisation. Clinical and Translational Immunology, 2019, 8, e1079.	1.7	40
36	lmmunosuppression and Allograft Rejection Following Lung Transplantation: Evidence to Date. Drugs, 2013, 73, 1793-1813.	4.9	35

#	Article	IF	CITATIONS
37	Outcomes of adolescent recipients after lung transplantation: An analysis of the International Society for Heart and Lung Transplantation Registry. Journal of Heart and Lung Transplantation, 2018, 37, 323-331.	0.3	35
38	Eleven Years On: A Clinical Update of Key Areas of the 1996 Lung Allograft Rejection Working Formulation. Journal of Heart and Lung Transplantation, 2007, 26, 423-430.	0.3	34
39	The Evolution of Lung Transplant Immunosuppression. Drugs, 2018, 78, 965-982.	4.9	33
40	Molecular phenotyping of rejectionâ€related changes in mucosal biopsies from lung transplants. American Journal of Transplantation, 2020, 20, 954-966.	2.6	33
41	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. Chest, 2020, 157, 1506-1512.	0.4	33
42	Donor Selection and Management. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 361-370.	0.8	32
43	Annexin A2 contributes to lung injury and fibrosis by augmenting factor Xa fibrogenic activity. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 312, L772-L782.	1.3	30
44	Senescence of IPF Lung Fibroblasts Disrupt Alveolar Epithelial Cell Proliferation and Promote Migration in Wound Healing. Pharmaceutics, 2020, 12, 389.	2.0	30
45	Cranial Leiomyosarcoma in an Epstein–Barr Virus (EBV)-mismatched Lung Transplant Recipient. Journal of Heart and Lung Transplantation, 2007, 26, 753-755.	0.3	29
46	Long-term outcomes of cadaveric lobar lung transplantation: Helping to maximize resources. Journal of Heart and Lung Transplantation, 2010, 29, 439-444.	0.3	29
47	Lung transplantation in Australia, 1986–2018: more than 30 years in the making. Medical Journal of Australia, 2018, 208, 445-450.	0.8	28
48	Casein Kinase 1Î′/ε Inhibitor, PF670462 Attenuates the Fibrogenic Effects of Transforming Growth Factor-β in Pulmonary Fibrosis. Frontiers in Pharmacology, 2018, 9, 738.	1.6	28
49	Self DNA perpetuates IPF lung fibroblast senescence in a cGAS-dependent manner. Clinical Science, 2020, 134, 889-905.	1.8	28
50	Effect of donor preservation solution and survival in lung transplantation. Journal of Heart and Lung Transplantation, 2011, 30, 414-419.	0.3	27
51	HLA class II Eplet mismatch predicts De Novo DSA formation post lung transplant. Transplant Immunology, 2018, 51, 73-75.	0.6	27
52	Inhibition of the K _{Ca} 3.1 Channel Alleviates Established Pulmonary Fibrosis in a Large Animal Model. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 539-550.	1.4	26
53	The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF. Scientific Reports, 2017, 7, 41770.	1.6	26
54	Lung transplantation. Current Opinion in Anaesthesiology, 2007, 20, 21-26.	0.9	25

#	Article	IF	CITATIONS
55	Cellular Microenvironment Stiffness Regulates Eicosanoid Production and Signaling Pathways. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 819-830.	1.4	25
56	Influenza, but not SARSâ€CoVâ€2, infection induces a rapid interferon response that wanes with age and diminished tissueâ€resident memory CD8 ⁺ T cells. Clinical and Translational Immunology, 2021, 10, e1242.	1.7	25
57	High Levels of Mannose-Binding Lectin Are Associated With Poor Outcomes After Lung Transplantation. Transplantation, 2011, 91, 1044-1049.	0.5	24
58	Antibody-Mediated Rejection in Lung Transplantation. Transplantation, 2014, 98, 927-930.	0.5	24
59	Perspectives on <i>Scedosporium</i> species and <i>Lomentospora prolificans</i> in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology, Transplant Infectious Disease, 2019, 21, e13141.	0.7	24
60	CXCR4+ cells are increased in lung tissue of patients with idiopathic pulmonary fibrosis. Respiratory Research, 2020, 21, 221.	1.4	23
61	Buying time: The use of extracorporeal membrane oxygenation as a bridge to lung transplantation in pediatric patients. Pediatric Transplantation, 2013, 17, E182-8.	0.5	21
62	The contribution of airway ischemia and vascular remodelling to the pathophysiology of bronchiolitis obliterans syndrome and chronic lung allograft dysfunction. Current Opinion in Organ Transplantation, 2010, 15, 558-562.	0.8	20
63	Sustained function of genetically modified porcine lungs in an ex vivo model of pulmonary xenotransplantation. Journal of Heart and Lung Transplantation, 2013, 32, 1123-1130.	0.3	20
64	CD8+ T cell landscape in Indigenous and non-Indigenous people restricted by influenza mortality-associated HLA-A*24:02 allomorph. Nature Communications, 2021, 12, 2931.	5.8	20
65	Nodular Glomerulosclerosis in Cystic Fibrosis Mimics Diabetic Nephropathy. Nephron Clinical Practice, 2004, 96, c70-c75.	2.3	19
66	Natural Killer Cell Activation in the Lung Allograft Early Posttransplantation. Transplantation, 2010, 89, 756-763.	0.5	19
67	Successful treatment of cytomegalovirus associated hemophagocytic lymphohistiocytosis with the interleukin 1 inhibitor – anakinra. Respirology Case Reports, 2016, 4, 4-6.	0.3	19
68	Portable oxygen concentrators versus oxygen cylinder during walking in interstitial lung disease: <scp>A</scp> randomized crossover trial. Respirology, 2017, 22, 1598-1603.	1.3	19
69	The complex existence of $\hat{I}^{\hat{J}}\hat{I}$ T cells following transplantation: the good, the bad and the simply confusing. Clinical and Translational Immunology, 2019, 8, e1078.	1.7	19
70	Long-Term Successful Outcomes From Kidney Transplantation After Lung and Heart-Lung Transplantation. Annals of Thoracic Surgery, 2015, 99, 1032-1038.	0.7	18
71	Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations. Journal of Antimicrobial Chemotherapy, 2018, 73, 748-756.	1.3	18
72	Cross-Reactive Anti-Viral T Cells Increase Prior to an Episode of Viral Reactivation Post Human Lung Transplantation. PLoS ONE, 2013, 8, e56042.	1.1	18

#	Article	IF	CITATIONS
73	The Presence of HLA-E-Restricted, CMV-Specific CD8+ T Cells in the Blood of Lung Transplant Recipients Correlates with Chronic Allograft Rejection. PLoS ONE, 2015, 10, e0135972.	1.1	18
74	Donor selection and management. Current Opinion in Organ Transplantation, 2009, 14, 471-476.	0.8	17
75	Donor risk prediction. Current Opinion in Organ Transplantation, 2013, 18, 507-512.	0.8	17
76	Molecular T-cell‒mediated rejection in transbronchial and mucosal lung transplant biopsies is associated with future risk of graft loss. Journal of Heart and Lung Transplantation, 2020, 39, 1327-1337.	0.3	17
77	Inhibition of NF-κB by ACT001 reduces fibroblast activity in idiopathic pulmonary fibrosis. Biomedicine and Pharmacotherapy, 2021, 138, 111471.	2.5	15
78	Longâ€ŧerm outcomes from bronchoscopic lung volume reduction using a bronchial prosthesis. Respirology, 2011, 16, 167-173.	1.3	14
79	Relationship between Trough Plasma and Epithelial Lining Fluid Concentrations of Voriconazole in Lung Transplant Recipients. Antimicrobial Agents and Chemotherapy, 2013, 57, 4581-4583.	1.4	14
80	Antibody-mediated rejection. Current Opinion in Organ Transplantation, 2015, 20, 492-497.	0.8	14
81	Donation after Brain Death versus Donation after Circulatory Death: Lung Donor Management Issues. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 138-147.	0.8	14
82	Evolution to twice daily bolus intravenous tacrolimus: Optimizing efficacy and safety of calcineurin inhibitor delivery early post lung transplant. Annals of Transplantation, 2013, 18, 399-407.	0.5	14
83	H1N1 Influenza: Critical Care Aspects. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 400-408.	0.8	13
84	Bronchoscopic procedures and lung biopsies in pediatric lung transplant recipients. Pediatric Pulmonology, 2015, 50, 1406-1419.	1.0	13
85	Evaluation of Quantiferon®â€Monitor as a biomarker of immunosuppression and predictor of infection in lung transplant recipients. Transplant Infectious Disease, 2021, 23, e13550.	0.7	13
86	Natural killer cell receptors regulate responses of HLA-E–restricted T cells. Science Immunology, 2021, 6, .	5.6	13
87	A Senescence Bystander Effect in Human Lung Fibroblasts. Biomedicines, 2021, 9, 1162.	1.4	12
88	Vascular remodelling in IPF patients and its detrimental effect on lung physiology: potential role of endothelial to mesenchymal transition (EndMT). ERJ Open Research, 2022, 8, 00571-2021.	1.1	12
89	Paediatric lobar lung transplantation: addressing the paucity of donor organs. Medical Journal of Australia, 2008, 189, 173-175.	0.8	11
90	Controlled donation after circulatory death (DCD) donors: A focus on the utilization of pediatric donors and outcomes after lung transplantation. Journal of Heart and Lung Transplantation, 2019, 38, 1089-1096.	0.3	11

#	Article	IF	CITATIONS
91	<i>Scedosporium apiospermum</i> and <i>Lomentospora prolificans</i> in lung transplant patients – A single center experience over 24Âyears. Transplant Infectious Disease, 2021, 23, e13546.	0.7	11
92	Lung transplantation in adults and children: Putting lung function into perspective. Respirology, 2014, 19, 1097-1105.	1.3	10
93	Transcripts associated with chronic lung allograft dysfunction in transbronchial biopsies of lung transplants. American Journal of Transplantation, 2021, , .	2.6	10
94	Enrichment of Cytomegalovirus-induced NKG2C+ Natural Killer Cells in the Lung Allograft. Transplantation, 2019, 103, 1689-1699.	0.5	9
95	Transfer of donor anti-HLA antibody expression to multiple transplant recipients: A potential variant of the passenger lymphocyte syndrome?. American Journal of Transplantation, 2019, 19, 1577-1581.	2.6	9
96	Proliferating Bronchial Webs After Lung Transplantation. Annals of Thoracic Surgery, 2011, 92, 1893-1896.	0.7	8
97	Managing Bronchiolitis Obliterans Syndrome (BOS) and Chronic Lung Allograft Dysfunction (CLAD) in Children: What Does the Future Hold?. Paediatric Drugs, 2013, 15, 281-289.	1.3	8
98	Consequences of donor-derived passengers (pathogens, cells, biological molecules and proteins) on clinical outcomes. Journal of Heart and Lung Transplantation, 2019, 38, 902-906.	0.3	8
99	Donor Lung Referrals for Lung Transplantation: A â€ [~] Behind The Scenes' View. Heart Lung and Circulation, 2020, 29, 793-799.	0.2	8
100	Outcomes Following Extracorporeal Photopheresis for Chronic Lung Allograft Dysfunction Following Lung Transplantation: A Single-Center Experience. Transplantation Proceedings, 2021, 53, 296-302.	0.3	8
101	Managing central venous obstruction in cystic fibrosis recipients—lung transplant considerations. Journal of Cystic Fibrosis, 2015, 14, 255-261.	0.3	7
102	Atrial Flutter and Fibrillation Following Lung Transplantation: Incidence, Associations and a Suggested Therapeutic Algorithm. Heart Lung and Circulation, 2020, 29, 1484-1492.	0.2	7
103	Cytomegalovirus replication is associated with enrichment of distinct Î ³ δT cell subsets following lung transplantation: A novel therapeutic approach?. Journal of Heart and Lung Transplantation, 2020, 39, 1300-1312.	0.3	7
104	Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection. Scientific Reports, 2020, 10, 1459.	1.6	7
105	Feasibility and Safety of a Transthoracic Pneumostoma Airway Bypass in Severe Emphysema Patients. Respiration, 2017, 93, 236-246.	1.2	6
106	Outcomes Following ATG Therapy for Chronic Lung Allograft Dysfunction. Transplantation Direct, 2021, 7, e681.	0.8	6
107	Abnormal one-year post-lung transplant spirometry is a significant predictor of increased mortality and chronic lung allograft dysfunction. Journal of Heart and Lung Transplantation, 2021, 40, 1649-1657.	0.3	6
108	Physical activity decline is disproportionate to decline in pulmonary physiology in IPF. Respirology, 2021, 26, 1152-1159.	1.3	6

#	Article	IF	CITATIONS
109	The influence of clinical donor factors on acute rejection among lung and kidney recipients from the same multi-organ donor. Annals of Transplantation, 2013, 18, 358-367.	0.5	6
110	Staphylococcus aureus specific lung resident memory CD4+ Th1 cells attenuate the severity of influenza virus induced secondary bacterial pneumonia. Mucosal Immunology, 0, , .	2.7	6
111	Real-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients. Journal of Heart and Lung Transplantation, 2022, 41, 1258-1267.	0.3	6
112	A spirometric journey following lung transplantation. Respirology Case Reports, 2014, 2, 120-122.	0.3	5
113	How can we improve the quality of transplantable lungs?. Expert Review of Respiratory Medicine, 2016, 10, 1155-1161.	1.0	5
114	Refractory Pulmonary Edema Caused by Late Pulmonary Vein Thrombosis After Lung Transplantation: A Rare Adverse Event. Annals of Thoracic Surgery, 2016, 102, e197-e199.	0.7	5
115	Clinical effectiveness of early posaconazole suspension pre-emptive therapy in lung transplant recipients: The Alfred's experience. Journal of Antimicrobial Chemotherapy, 2017, 72, 2089-2092.	1.3	5
116	Activin Biology After Lung Transplantation. Transplantation Direct, 2017, 3, e159.	0.8	5
117	Risk Indices in Deceased-donor Organ Allocation for Transplantation: Review From an Australian Perspective. Transplantation, 2019, 103, 875-889.	0.5	5
118	Challenges inherent to the diagnosis of antibodyâ€nediated rejection in lung transplantation. Respirology Case Reports, 2015, 3, 36-39.	0.3	4
119	Breathing life into lung transplant mortality definitions and reporting. Journal of Heart and Lung Transplantation, 2019, 38, 1228-1230.	0.3	4
120	Prolonged survival after lung transplantation in the absence of conventional immunosuppression. Journal of Heart and Lung Transplantation, 2020, 39, 1159-1162.	0.3	4
121	Non-Bronchiolitis Obliterans Syndrome Forms of Chronic Lung Allograft Dysfunction. , 2013, , 47-58.		4
122	Angiotensin-Converting Enzyme 2 (ACE2), Transmembrane Peptidase Serine 2 (TMPRSS2), and Furin Expression Increases in the Lungs of Patients with Idiopathic Pulmonary Fibrosis (IPF) and Lymphangioleiomyomatosis (LAM): Implications for SARS-CoV-2 (COVID-19) Infections. Journal of Clinical Medicine, 2022, 11, 777.	1.0	4
123	Cytomegaloviral infection and other infections related to lung allograft survival. Current Opinion in Organ Transplantation, 2004, 9, 342-349.	0.8	3
124	The parable of the lobes and the fissures. Respirology, 2014, 19, 465-466.	1.3	3
125	Supplemental oxygen and dypsnoea in interstitial lung disease: absence of evidence is not evidence of absence. European Respiratory Review, 2017, 26, 170072.	3.0	3
126	γδT Cells in Transplantation: Friend and Foe. Transplantation, 2018, 102, 1970-1971.	0.5	3

#	Article	IF	CITATIONS
127	Endobronchial fusariosis in a child following bilateral lung transplant. Medical Mycology Case Reports, 2019, 23, 77-80.	0.7	3
128	Lung allograft standardized histological analysis (LASHA) template: A research consensus proposal. Journal of Heart and Lung Transplantation, 2022, 41, 1487-1500.	0.3	3
129	Reply to Meylan and Zanetti. Journal of Infectious Diseases, 2005, 191, 2153-2154.	1.9	2
130	Immunosuppression for lung transplant recipients. Current Respiratory Care Reports, 2014, 3, 88-95.	0.6	2
131	Cyclophosphamide for connective tissue disease-associated interstitial lung disease. The Cochrane Library, 2014, , .	1.5	2
132	Numerous Howell-Jolly bodies in a patient with idiopathic splenic calcification. British Journal of Haematology, 2015, 169, 767-767.	1.2	2
133	The potential role of activin and follistatin in lung transplant dysfunction. Expert Review of Respiratory Medicine, 2015, 9, 697-701.	1.0	2
134	Coagulation factor-XII induces interleukin-6 by primary lung fibroblasts: a role in idiopathic pulmonary fibrosis?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2022, 322, L258-L272.	1.3	2
135	Lungs don't grow on trees: The ethics of increasing organ donation rates for transplantation and their relevance to the Asiaâ€Pacific region. Respirology, 2007, 12, 631-633.	1.3	1
136	Successful lung transplantation for adolescents at a hospital for adults. Medical Journal of Australia, 2008, 188, 430-431.	0.8	1
137	The clinical utility and thresholds of virtual and Halifaster flow crossmatches in lung transplantation. Hla, 2022, 99, 580-589.	0.4	1
138	Lung transplant survival despite unexpected pulmonary metastatic thyroid cancer in the explant. Transplant International, 2010, 23, no-no.	0.8	0
139	P073 <break></break> The role of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis QJM - Monthly Journal of the Association of Physicians, 0, , .	0.2	0
140	Sequential unilateral lung volume reduction for emphysema - Stretching the benefit. Respiratory Medicine Case Reports, 2017, 20, 120-122.	0.2	0
141	Lung Transplant Primary Graft Dysfunction. , 2022, , 719-728.		0
142	Severe Hemolysis Due to Passenger Lymphocyte Syndrome in Three Recipients of Organs from a Donor with Multiple Red Cell Alloantibodies Blood, 2007, 110, 4023-4023.	0.6	0
143	Antibody Mediated Rejection: Are We There Yet?. , 2019, , 79-86.		0
144	High Precursor Frequency and Promiscuity in Î [°] β T Cell Receptor Pairing Underpin CD8+ T-Cell Responses to an Immunodominant SARS-CoV-2 Nucleocapsid Epitope. SSRN Electronic Journal, 0, , .	0.4	0